The Role of Chronotropic Incompetence in Heart Failure With Normal Ejection Fraction (HFNEF)

February 3, 2015 updated by: University of Oxford

A Mechanistic Study to Assess The Role of Chronotropic Incompetence in Heart Failure With Normal Ejection Fraction (HFNEF)

What is heart failure with normal ejection fraction? The heart contracts (pumps) and relaxes with each heartbeat. In some people with heart failure, the heart contracts normally but there is reduced relaxation of the heart. As a result, people notice a feeling of breathlessness, ankle swelling and fatigue especially on exertion.

The investigators feel that patients with reduced or impaired relaxation of the heart have less heart filling time and poor energy utilisation during exercise. Therefore, the investigators are conducting a study to more thoroughly understand the disease condition by giving a drug called ivabradine to reduce the heart rate and hence to increase the heart filling time in these patients.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

BACKGROUND AND RATIONALE About 50% of patients with heart failure have a normal ejection fraction (HFNEF). Although traditionally considered a more benign disorder than the related heart failure with reduced ejection fraction (HFREF), the mortality figures for patients with HFNEF and HFREF are now known to be comparable. Surprisingly, despite HFNEF's importance as a major health concern, the pathophysiological basis of HFNEF's remains poorly understood with some commentators even suggesting that HFNEF's pathophysiology is a variant of HFREF. Further confounding the understanding of HFNEF, existing studies included heterogenous patients of stratified ethnicities and ages who were assessed at rest. Such patients may not exhibit the same physiology as the typically elderly female HFNEF patients who experience symptoms during exertion.

Elucidating the mechanisms underlying HFNEF is pressing as there is a paucity of evidence to even begin to guide therapy. In the absence of supportive trial evidence, clinical practice has been predicated on assumptions made regarding the physiology of diastolic (dys)function. For example, rate limitation is often advocated in HFNEF based on the 19th century observations by Lewis Katz that at higher heart rates, shortening of diastolic filling period impairs cardiac filling and results in lower stroke volumes.

Such empirical practices are beset by HFNEF's complexity. A consistent feature of HFNEF is reduced chronotropic reserve. In one study HFNEF patients were assessed invasively using pressure-volume loops during basal conditions and handgrip exercise with atrial pacing at 120bpm. It was concluded that at higher heart rates, there was a significant blunting of frequency-dependent ventricular relaxation and that rate-related diastolic chamber stiffness compromised stroke volume explaining exertional limitation. Other investigators have disputed the aberrancy of diastolic filling limitation, questioning the potential benefits of heart rate limitation using beta-blockers and raising the potential for pacing as a treatment for HNEF. We confirmed the impaired chronotropic reserve in HFNEF. We also demonstrated dynamic slowing of LV relaxation during exercise that was associated with and potentially attributable to impaired cardiac energetics (albeit at rest)9. However, to determine the pertinence of heart rate to inadequate exertional reserve in HFNEF, heart rate needs to be manipulated in the complex neurohormonal, autonomic and haemodynamic context of exercise. The fundamental limitation of existing studies, including those utilizing pacing and handgrip, is that exercise physiology was not recapitulated.

Cardiac MR is the most accurate and versatile method for phenotyping the heart in research studies, and can assess cardiac volumes and mass with unparalleled accuracy and reproducibility. 31P MRS is the only technique that allows non-invasive measurement of cardiac high-energy phosphate metabolism in vivo. Our department has developed a 31P-MRS protocol which allows for measuring high energy phosphate molecules at rest and during exercise Cardiopulmonary exercise testing with peak oxygen consumption measurement has been shown to be a reliable mechanistic readout of integrated cardiac function in heart failure with preserved ejection fraction9,. It is also safe and reliable in elderly patients with heart failure.

In summary, chronotropic incompetence could either be a compensatory phenomenon serving to limit cardiac energetic depletion on exercise and also increasing diastolic filling in the context of an abbreviated diastolic filling time due to dynamic slowing of active relaxation. Alternatively it might contribute to exercise limitation by limiting cardiac output augmentation on exercise (since cardiac output is the product of heart rate and stroke volume). In order to investigate this LV filling and cardiac output pathophysiology in HFNEF, we will employ Ivabradine, that reduces heart rate but has no direct effect on contractile/lusitropic function or on vascular tone.

Ivabradine is indicated in symptomatic chronic stable angina patients who are unable to tolerate or with a contra-indication to the use of beta-blockers. It can be used in combination with beta-blockers whose heart rate is > 60 bpm. We will use ivabradine as a pharmacological tool to investigate diastolic filling/function and hence its effect on cardiac function and metabolism of energy. Ivabradine dose has been extensively validated and deemed safe in the a previous study (Beautiful study). The common side effects are transient enhanced brightness in a limited area of the visual field, usually triggered by sudden variations in light intensity and blurred vision. Other common side effects are bradycardia, headache and dizziness possibly related to bradycardia.

Ivabradine is metabolised by CYP3A4 and the concomitant use of potent CYP3A4 inhibitors such as azole antifungals (ketoconazole, itraconazole), macrolide antibiotics (clarithromycin, erythromycin, josamycin, telithromycin), HIV protease inhibitors and nefazodone is contraindicated. The combination of ivabradine with the heart rate reducing agents diltiazem or verapamil is not recommended. Other drugs which combination with ivabradine is not recommended are QT prolongation drugs (quinidine, disopyramide, bepridil, sotalol, ibutilide, amiodarone, pimozide, ziprasidone, sertindole, mefloquine, halofantrine, pentamidine). Combination of ivabradine with beta-blockers, ACE inhibitors, angiotensin II antagonists, diuretics, short and long acting nitrates, HMG CoA reductase inhibitors, fibrates, proton pump inhibitors, oral antidiabetics, aspirin, and other anti-platelet agents has been found to be safe.

Although not a clinical trial, we will assess the impact of lowering heart rate on exercise in patients with HFNEF and in matched patients with hypertension but no exercise limitation in order to begin to understand the role of heart rate in diastolic physiology.

Patient selection Through our HFNEF community screening programme, and via heart failure clinics in Oxford we will identify 30 patients with HFNEF who meet ESC criteria and additionally have peak VO2 ≤ 85% with a cardiac pattern of exercise limitation during CPEX; 30 matched hypertensive controls without HFNEF (no subjective complaint of breathlessness and peak V02 > 90% of age and gender predicted) will be recruited and studied in Aberdeen by a research team led by Professor Michael Frenneaux. 20 matched healthy subjects will be recruited in Oxford to provide normal reference values for study examinations at baseline.

STUDY DESIGN Summary of study design This research project has 3 groups and will be done in 2 different centres, Oxford and Aberdeen. Both HFNEF and hypertensive controls (positive controls) will participate in a prospective, randomized, double-blind, placebo-controlled crossover design consisting of two experimental periods (Ivabradine 7.5mg bd vs placebo each for two weeks with two weeks washout in between). Normal controls (negative controls) will only undergo baseline assessments and will not be given Ivabradine or placebo.

Group 1 (University of Oxford) This will be done by a research team led by Dr Houman Ashrafian and Prof S Neubauer.

30 patients with HFNEF, who are at least 60 years old will be recruited from the heart failure clinic at the John Radcliffe Hospital or the HFNEF community screening programme in Oxford over a 24-month period. Only those with VO2max of ≤ 85% with a cardiac pattern of exercise limitation during CPEX at screening will be included in the study.

At the end of screening visit, all eligible subjects will be randomly assigned to one of the possible experimental sequences. Each subject will receive either Ivabradine 7.5mg bd or matching placebo tablets (Period 1), followed by a 2-week washout period, and then placebo or Ivabradine 7.5mg bd for the final 2-week period (Period 2). The subject and study investigators will be blind to the randomization schedule. Patients will be evaluated at baseline and at the end of the two experimental periods in John Radcliffe hospital. All the evaluation days will last approximately 4 hours.

Elderly participants will be allowed to perform MRI/MRS on the next day.

Group 2 (University of Aberdeen) This will be done by a research team led by Professor Michael Frenneaux. 30 matched hypertensive controls, without heart failure symptoms who are at least 65 years old will be recruited in Aberdeen over a 24-month period. Only those with VO2max of > 90% predicted during CPEX at screening will be included in the study.

Elderly participants will be allowed to perform nuclear study or MRI/MRS on the next day.

Group 3 (Normal Subjects) 20 matched normal controls, who are at least 18 years old will be recruited in Oxford over a 24-month period. All participants will only undergo Visit 1 tests and will not be given Ivabradine or placebo.

Study Procedures Eligibility of patients will be checked by predefined inclusion/exclusion criteria at the time of attendance to the heart failure clinic (Oxford), cardiology clinics, cardiac investigation department and other relevant clinics in John Radcliffe hospital (such as hypertension, diabetes e.t.c.) or hypertension/cardiology clinic (Aberdeen Royal Infirmary) by the clinical team.

Informed Consent Written and verbal explanation of the study aims and protocol will be provided detailing the exact nature of the study, the implications and constraints of the protocol and the known possible side effects and any risks involved in taking part.

Study Assessments

Screening visit, 1-2 hours

  1. Check for eligibility
  2. Obtain written informed consent
  3. History and physical examination

  4. Cardiopulmonary exercise testing (CPEX)

    • VO2 max.
    • Ventilatory efficiency (VE/VCO2)
    • Respiratory exchange ratio
    • Lactate level (optional)

    Only those eligible [peak V02 ≤ 85% with a cardiac pattern of exercise limitation during CPX (Group 1, Oxford) or peak V02 > 90% (Group 2, Aberdeen)] will continue with rest of screening visit study procedures. Participants who are not eligible will be withdrawn from the study at this point.

  5. To complete MLHFQ
  6. Resting ECG
  7. Bloods (10ml draw) for FBC, renal profile, fasting glucose, cholesterol, liver function, FFA and BNP.

At the end of screening visit, subjects will be randomly assigned to either Ivabradine 7.5mg twice daily or matching placebo tablets for 2 weeks (Period 1).

Visit 1 (4 hours, 2 weeks after starting Period 1 - Ivabradine/placebo) All assessments at screening will be repeated (barring seeking written consent again) and all experimental agents will be stopped. Additionally a cardiac MRI scan will be performed.

Visit 2 (4 hours, 2 weeks after starting Period 2 - placebo/Ivabradine) All visit 1 assessments will be repeated and all tablets will be stopped. All subjects will be requested to return all unused tablets from the Period 2. The study will end at the end of Visit 2.

Healthy volunteers (group 3) will only undergo all assessments as a single visit and will not undergo CPEX screening test or given a study drug.

Study Type

Interventional

Enrollment (Actual)

121

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United Kingdom
      • Oxford, United Kingdom, OX3 9DU
        • Univesrtity of Oxford, John Radcliffe Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

60 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Participant who is willing and able to give informed consent for participation in the study.
  • Male or Female, aged 60 years and over (Group 1, Oxford).
  • Patients diagnosed with HFNEF by ESC criteria and have peak V02 ≤ 85% with a cardiac pattern of exercise limitation during CPEX (Group 1, Oxford).
  • Hypertensive controls aged 65 and over without HFNEF and with peak V02 > 90% (Group 2, Aberdeen)
  • Able to perform exercise testing.

Exclusion Criteria:

The participant may not enter the study if ANY of the following apply:

  • LVEF <50%
  • Inability to tolerate MRI scanning (claustrophobia, inability to lie flat)
  • Contraindications to CMR imaging (implantable devices or other metal implants, internal cardioverter-defibrillator, cranial aneurysm clips, metallic ocular foreign bodies, hypersensitivity to gadolinium)
  • Presence of other significant concomitant diseases such as ischaemic, valvular, pericardial heart disease or cardiomyopathy.
  • Presence of asthma (contraindication to adenosine)
  • Presence of 2nd or 3rd degree AV block (contraindications to ivabradine and adenosine)
  • Presence of sick sinus syndrome
  • Presence of atrial fibrillation
  • Significant bradycardia (HR <60 per minute).
  • Objective evidence of lung disease on formal lung function testing
  • Female participant who is pregnant, lactating or planning pregnancy during the course of the study
  • Unable to perform exercise testing
  • Patient who is in terminally ill or is inappropriate for medication
  • Known hypersensitivity to Ivabradine or adenosine
  • Significantly impaired renal function (eGFR<30ml/min)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Active arm
All subjects will receive Ivabradine 7.5mg twice daily for 2 weeks in a double-blind randomized crossover design.
Drug: Ivabradine
All subjects will receive Ivabradine 7.5mg twice daily for 2 weeks in a double-blind randomized crossover design.
Other Names:
  • Procoralan
Placebo Comparator: Placebo arm
All subjects will receive matching placebo tablets twice daily for 2 weeks in a double-blind randomized crossover design.
Drug: Ivabradine
All subjects will receive Ivabradine 7.5mg twice daily for 2 weeks in a double-blind randomized crossover design.
Other Names:
  • Procoralan

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Change in VO2max measured by CPEX
Time Frame: After 2 weeks of intervention
After 2 weeks of intervention

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Doppler derived E/e'
Time Frame: After 2 weeks of intervention
ECHO derived parameter
After 2 weeks of intervention
BNP (Brain natriuretic peptide)
Time Frame: After 2 weeks of intervention
After 2 weeks of intervention
Minnesota Living with Heart Failure Questionnaire (MLHFQ)
Time Frame: After 2 weeks of intervention
Quality of life assessed by the MLHFQ.
After 2 weeks of intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Oxford

Collaborators

University of Aberdeen

Investigators

  • Principal Investigator: Houman Ashrafian, MRCP, University of Oxford

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

December 1, 2011

Primary Completion (Actual)

January 1, 2014

Study Completion (Actual)

January 1, 2014

Study Registration Dates

First Submitted

January 29, 2015

First Submitted That Met QC Criteria

February 2, 2015

First Posted (Estimate)

February 3, 2015

Study Record Updates

Last Update Posted (Estimate)

February 4, 2015

Last Update Submitted That Met QC Criteria

February 3, 2015

Last Verified

August 1, 2013

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 11/SC/0009

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Heart Failure

Clinical Trials on Ivabradine

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mozambique

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe